Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Fetal Interventricular Septum Thickness and Maternal Gestational Diabetes Control

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03654521
Recruitment Status : Recruiting
First Posted : August 31, 2018
Last Update Posted : August 31, 2018
Sponsor:
Information provided by (Responsible Party):
Yaniv Zipori MD, Rambam Health Care Campus

Brief Summary:

Glucose intolerance and gestational diabetes are common complications of pregnancy. Their prevalence varies worldwide secondary to differences in screening practices (one-step versus two-step approach) and population characteristics (increased maternal age, body mass index, ethnicity). Gestational diabetes mellitus is associated with increased incidence of macrosomia, operative vaginal delivery, shoulder dystocia, cesarean delivery, metabolic complications in the newborn and long-term risk of developing type II diabetes mellitus (HAPO 2008).

Early diagnosis and management of gestational diabetes mellitus, including dietary advice and insulin, improves maternal and fetal outcomes (Crowther 2005, Hartling 2013). Various strategies have been tested prenatally to detect those fetuses that might be adversely affected by gestational diabetes mellitus. For instance, the abdominal circumference measurement during routine fetal biometry was used successfully to identify pregnancies with a higher risk of fetal macrosomia (Schaefer-Graf 2003, De Reu 2008, Rosati 2010). In recent years, the fetal interventricular septum thickness, as detected by two-dimensional ultrasound, was shown to be significantly thicker in the presence of gestational diabetes mellitus, independently of maternal glycemic control, when compared to pregnancies with no gestational diabetes mellitus (Ren 2011, Garg 2014).

Current guidelines focus on normalisation of maternal blood glucose concentration. Thus far no study has addressed whether measurement of the fetal interventricular septum thickness can predict adverse pregnancy outcome in euglycemic women with gestational diabetes mellitus.


Condition or disease Intervention/treatment Phase
Gestational Diabetes Diagnostic Test: Fetal interventricular septum thickness Not Applicable

Detailed Description:

Rational for the study If fetal interventricular septum hypertrophy in pregnancies with gestational diabetes mellitus appears prior to either fetal abdominal circumference measurement > 90th percentile or the abnormal maternal glucose levels, then future management of women with gestational diabetes mellitus might be targeted earlier at these pregnancies to ensure a more favorable outcome.

Objective To determine the thickness of fetal interventricular septum in women with and without gestational diabetes mellitus and correlates it with perinatal outcome.

Methods Study design This is a prospective study at Rambam Health Care Campus. Inclusion / Exclusion criteria

  1. Inclusion Study group - women between 24 - 34 weeks' gestation who were diagnosed with gestational diabetes mellitus or known with type I or type II diabetes mellitus.

    Control group - women between 24 - 34 weeks' gestation who do not have diabetes.

  2. Exclusion (that might affect directly or indirectly the fetal cardiac function) - women who did not complete a glucose challenge test, smoking, underlying cardiac or respiratory illness, fetal growth restriction, medicated hypertension disorder of pregnancy, multiple pregnancy, use of steroids for lung maturation in the current pregnancy and known major congenital anomalies.

Study population Women who meet the above inclusion criteria will be asked to participate in the study, and will be asked to provide a written informed consent. Both groups, the study and control group, will be recruited when attending their routine prenatal care in the prenatal clinics at Rambam Health Care Campus. Eligible woman will undergo ultrasound examination as they would normally do in each visit. This study, under no circumstances, will alter the participants routine care.

Data Collection

  1. Maternal and fetal characteristics Data related to the fetomaternal antenatal, intrapartum and postpartum course will be recorded prospectively (Appendix 1).
  2. Ultrasound assessment Basic transabdominal two-dimensional ultrasound examination using B-mode (either Samsung or Voluson E8), will be carried out first to assess fetal growth and well-being. This is to be continued with a more detailed ultrasound, with a specific focus on the fetal interventricular septum. The entire length of the study, dependent on fetal lie, is expected to take around 15 min. The results of the assessment of fetal growth and well-being will be provided to the patient.

The measurement of the fetal interventricular septum will be as follow (Figure 1 below); maternal suspended respiration, without fetal movement or breathing, level of the 4-chamber view with adequate magnification of the fetal heart (50% of the screen), midpoint of interventricular septum with cine loop to end-diastolic (maximum ventricular filling), and average of 3 measurements (Ren 2011, Garg 2014).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Fetal Interventricular Septum Thickness and Maternal Gestational Diabetes Control
Actual Study Start Date : August 1, 2018
Estimated Primary Completion Date : July 15, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Diabetes group
Women with gestational or pre-gestational diabetes mellitus.
Diagnostic Test: Fetal interventricular septum thickness
Two-dimensional ultrasound fetal cardiac imaging test

Active Comparator: Control group
Women without gestational or pre-gestational diabetes mellitus.
Diagnostic Test: Fetal interventricular septum thickness
Two-dimensional ultrasound fetal cardiac imaging test




Primary Outcome Measures :
  1. Fetal interventricular septum thickness [ Time Frame: Between 24-34 weeks of gestation. ]
    Differences in fetal interventricular septum thickness in both women with gestational or pre-gestational diabetes mellitus and women without gestational or pre-gestational diabetes mellitus.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 44 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Study group - women between 24 - 34 weeks' gestation who were diagnosed with gestational diabetes mellitus or known with type I or type II diabetes mellitus.

Control group - women between 24 - 34 weeks' gestation who do not have diabetes.

Exclusion Criteria:

  • women who did not complete a glucose challenge test, smoking, underlying cardiac or respiratory illness, fetal growth restriction, medicated hypertension disorder of pregnancy, multiple pregnancy, use of steroids for lung maturation in the current pregnancy and known major congenital anomalies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03654521


Contacts
Layout table for location contacts
Contact: Yaniv Zipori, MD 0587966963 y_zipori@rambam.health.gov.il

Locations
Layout table for location information
Israel
Rambam health care campus Recruiting
Haifa, Israel
Contact: Yaniv Zipori, MD    0587966963    y_zipori@rambam.health.gov.il   
Sponsors and Collaborators
Rambam Health Care Campus
Investigators
Layout table for investigator information
Principal Investigator: Yaniv Zipori, MD Rambam Health Care Campus

Layout table for additonal information
Responsible Party: Yaniv Zipori MD, Principal Investigator, Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT03654521     History of Changes
Other Study ID Numbers: 0580-17-RMB
First Posted: August 31, 2018    Key Record Dates
Last Update Posted: August 31, 2018
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes, Gestational
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pregnancy Complications